全身PET/MRI在黏液样脂肪肉瘤分期中的效用研究
回顾性分析2015至2022年31例黏液样脂肪肉瘤患者,10例按NCCN指南标准分期,21例采用全身PET(PET/MRI或PET/CT)分期。全身PET组初诊时3例(14.3%)发现转移,标准组无转移;随访中标准组2例、全身PET组3例出现新转移。作者认为全身PET对初诊转移和随访新发病灶的检出似乎至少不劣于现行NCCN指南推荐方式,但鉴于黏液样脂肪肉瘤对PET的亲和力低,PET的附加价值可能有限。
要点
- 黏液样脂肪肉瘤易转移至非典型部位,分期时需覆盖全身而非仅胸部。
- 原发灶中位SUVmax为2.8(范围2.3–3.4),提示肿瘤对FDG亲和力低。
- 全身PET组初诊转移检出3例(14.3%),标准组初诊无转移检出。
核心结论
- 全身PET(PET/MRI或PET/CT)用于黏液样脂肪肉瘤分期,似乎至少与现行NCCN指南推荐方式同样能检出初诊转移和随访中的新发病灶;但鉴于黏液样脂肪肉瘤的FDG亲和力低,PET成像的附加价值可能有限。
研究设计与样本
- 回顾性分析2015至2022年31例黏液样脂肪肉瘤患者,10例按标准指南分期,21例采用全身PET(PET/MRI或PET/CT)分期;排除未完成任何分期或在本院以外完成确定性治疗者。
关键影像表现/征象
- 原发肿瘤部位的中位SUVmax为2.8(范围2.3,3.4)。
- 随访影像检出的转移灶中位SUVmax:全身PET组为3.2,标准组为2.6。
诊断标准与关键数值
- 全身PET组初诊时3例(14.3%)发现转移,标准组初诊时无转移发现。
- 随访期间标准组(n=10)2例经胸部CT伴或不伴脊柱MRI发现新转移。
- 随访期间全身PET组3例出现新转移,其中1例经全身PET/MRI发现、2例经脊柱MRI发现。
临床应用与阅片要点
- 作者认为全身PET方式在初诊分期和随访中检出黏液样脂肪肉瘤转移似乎至少不劣于现行NCCN指南推荐方式。
- 作者指出鉴于黏液样脂肪肉瘤FDG亲和力低,PET成像的附加价值可能有限。
局限性
- 原文为回顾性分析,样本量为31例。
- 原文结论使用「appear to」和「may be limited」等限定表述,提示结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Myxoid liposarcoma is a soft tissue sarcoma with a unique predilection for metastasis to atypical sites compared to other soft tissue sarcoma histologic subtypes. Does a whole-body (PET/MRI or PET/CT) staging approach, compared to current National Comprehensive Cancer Network (NCCN) guidelines, improve our ability to identify metastatic disease in myxoid liposarcoma?
MATERIALS AND METHODS: A retrospective analysis identified 31 patients diagnosed with myxoid liposarcoma between 2015 and 2022. Ten patients were staged with standard guidelines and 21 with a whole-body PET modality. Patients who did not complete any staging or had their definitive care performed outside our institution were excluded.
RESULTS: In the whole-body group, three (14.3%) patients were found to have metastatic disease on initial presentation, while none had metastatic disease in the standard group. During post-treatment surveillance, two patients in the standard group (n = 10) had new metastases discovered by CT chest with/without MRI spine. Three patients in the whole-body group developed new metastases, which were discovered by whole-body PET/MRI in one and MRI spine in two patients. The median SUVmax of the primary tumor site was 2.8 (range 2.3, 3.4), and for metastasis detected on follow-up imaging, the median SUVmax was 3.2 and 2.6 for the whole-body and standard groups, respectively.
CONCLUSIONS: Whole-body PET modalities for staging myxoid liposarcoma appear to detect initial metastatic disease and new disease during surveillance, at least as well as current NCCN guideline-recommended modalities. Given that the avidity of myxoid liposarcoma is low, the added value of PET imaging may be limited.
引用
- Fan C, Williams-Medina E, Zhu K, et al. What is the utility of whole-body PET/MRI in the staging of myxoid liposarcoma? Skeletal Radiol. 2025. PMID: 41372708. doi:10.1007/s00256-025-05087-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。